Dosage Forms

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

Figures published by the European Medicines Agency (EMA) relating to centralized procedure activities for human medicines show a significant increase in the number of positive opinions made between 2007 and 2009; however, the majority of approvals are for generic products.

EMA figures demonstrate generic dominance

EMA statistics highlighting centralized-procedure activities for human medicines show a significant increase in positive opinions made between 2007 and 2009.

EMA Statistics Reveal Generic Dominance

The Director General of the European Generic medicines Association (EGA) has reiterated the association?s Vision 2015 plan, which aims to create a globally competitive generic industry, increase patient access to affordable quality medicines and ensure sustainable healthcare in Europe.

Plan outlined for European generics

The Director-General of the European Generic medicines Association has reiterated the group's Vision 2015 plan.

New Plan for Generic Drugs in Europe

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Hospira, a specialty pharmaceutical company, has agreed to acquire Orchid Chemicals' Pharmaceuticals for $400 million.

Hospira to Acquire Orchid's Generic Injectable Pharmaceutical Business

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Generic-drug manufacturers look to expand into biologics and complex dosage forms. This article contains bonus online-exclusive material.

Generic Drugs Come of Age

Leading experts from an upcoming conference on biosimilars by the Drug, Chemical, and Associated Technologies Association share their insights on the manufacturing and regulatory considerations for biosimilars.

Manufacturing and Regulatory Considerations in Biosimilars

The global API market has expanded from $69 billion in 2004 to more than $90 billion in 2008 at an average yearly growth rate of 7.2%, according to a report from the Italian Chemical Pharmaceutical Association (CPA).

Generic APIs outstrip innovation

The global API market has expanded from $69 billion in 2004 to more than $90 billion in 2008, according to a report from the Italian Chemical Pharmaceutical Association (CPA); in particular, the report noted a rapid growth rate for generic APIs.

Generic APIs Outstrip Innovation

Cheaper generic pharmaceuticals, emboldened by US law and patent challenges, restrict novel future innovations.